drugset / Trial / NCT04340076
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Phase 4
Completed
244 enrolled
Radboud University Medical Center
Belgium Health Care Knowledge Centre · collabUniversity Hospital, Ghent · collabZonMw: The Netherlands Organisation for Health Research and Development · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.
Timeline
- Start
- 2020-08-20
- Primary completion
- 2025-01-30
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimekizumab | Monoclonal antibody | 320 mg | — |
| Subject | Brodalumab | Monoclonal antibody | 210 mg | — |
| Subject | Guselkumab | Monoclonal antibody | 100 mg | — |
| Subject | Ixekizumab | Monoclonal antibody | 80 mg | — |
| Subject | Risankizumab | Monoclonal antibody | 150 mg | — |
| Subject | Secukinumab | Monoclonal antibody | 300 mg | — |
| Subject | Tildrakizumab | Monoclonal antibody | 100 mg | — |
| Subject | Tildrakizumab | Monoclonal antibody | 200 mg | — |